Johnson & Johnson has been fined once again for its antipsychotic drug, Risperdal.
An judge has fined the company’s Janssen subsidiary more than $1.1 billion after an Arkansas jury decided the company downplayed the drug’s risks when it prescribed Risperdal for other ailments besides the ones it had been approved to treat.
This is the second Risperdal verdict for the company. In December, J&J was fined $327 million in a similar case in South Carolina.
The Inquirer reports the company has already settled a case in Texas and has also lost a case in Louisiana to the tune of $258 million. Janssen is seeking a new trial or an appeal in Arkansas.